Sudeep Pharma (SUDEEPPHRM) Q4 25/26 earnings summary

Executive summary

• Achieved record revenue of Rs. 642.3 crore in FY26, a 28% year-over-year increase, driven by organic growth and strategic acquisitions.

• Successfully listed on BSE and NSE on 28 November 2025, raising net proceeds of INR 8,833.59 lakhs and enhancing long-term growth prospects.

• Acquired 85% stake in Nutrition Supplies Services (Ireland) Limited, expanding advanced formulation capabilities and European market reach.

• Initiated construction of a battery materials plant in Dahej, targeting battery-grade iron phosphate for LFP batteries.

• Audited consolidated and standalone financial results for FY26 received unmodified opinions from statutory auditors.

Financial highlights

• FY26 consolidated revenue from operations rose 28% year-over-year to Rs. 642.3 crore; Q4FY26 revenue up 16% YoY to Rs. 182.3 crore.

• FY26 EBITDA increased 17% to Rs. 221.9 crore; EBITDA margin at 34.6%.

• FY26 PAT grew 26% to Rs. 174.3 crore; PAT margin at 27.1%.

• EPS for FY26 at 15.50, up from 12.79 in FY25.

• Net debt/equity reduced to 0.04x in FY26, reflecting strong balance sheet discipline.

Outlook and guidance

• Battery materials plant at Dahej expected to be commissioned by early CY2027, with Phase 1 capacity of 25,000 MT.

• Greenfield project at Nandesari progressing, with customer validation trials ongoing; full ramp-up expected in 6–12 months.

• Working capital cycle expected to normalize as inventory turnover improves and supply chain disruptions ease.

• Unutilized IPO proceeds of Rs. 1,252.19 lakhs are kept as term deposits, pending deployment.

• Continued focus on expanding global reach, specialty ingredients, and battery materials segments.